Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and healthy sufficient to tolerate FCR therapy, should be superior candidates with the latter, with the advantage remaining that this treatment method might be done in six months though ibrutinib must be taken indefinitely. This option could well be particularly important for non